SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.

KB407’s positive set of results presented at ATS 2026 follows a set of similar positive results that were announced for the first two cohorts in December 2024.

Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vertex Pharmaceuticals Incorporated VRTX is a clear leader in the global cystic fibrosis (CF) market. The company has built a ...

A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes in individuals with cystic ...

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.

Please provide your email address to receive an email when new articles are posted on . Lung function in pregnant women with cystic fibrosis not using CFTR modulators went down after pregnancy. There ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...